PLUTO IMMUNOTHERAPEUTICS
Pluto Immunotherapeutics develops and researches different ways to treat cancer. It works with innovating and building cellular immunotherapies. Pluto Immunotherapeutics was founded in 2020 and is based in California, USA.
PLUTO IMMUNOTHERAPEUTICS
Industry:
Health Care Therapeutics Wellness
Founded:
2020-01-01
Address:
Los Angeles, California, United States
Country:
United States
Status:
Active
Similar Organizations
Anatomy
Anatomy is a chiropractic and physical therapy center.
BehaVR
BehaVR develops evidence-based, immersive, digital therapeutics for behavioral health using Virtual Reality.
Enosi Life Sciences
Enosi Life Sciences is a drug research and development company providing therapeutics for autoimmune diseases and cancer.
Hickory Recovery Network
Hickory Recovery Network provides drug addiction treatment programs.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Rosetta Genomics
Rosetta Genomics discovers, develops and commercializes diagnostic tests for personalized medicine.
SHEPHERD Therapeutics
SHEPHERD Therapeutics specializes in finding cure to rare cancers.
More informations about "Pluto Immunotherapeutics"
Pluto Immunotherapeutics, Inc. - Incubating Companies
Pluto's platform system is the best-in-class for generating mature T cells from pluripotent stem cells (PSC) capable of producing off-the-shelf products. ... Pluto Immunotherapeutics; Prosper โฆSee details»
Pluto Immunotherapeutics - Crunchbase Company Profile & Funding
Pluto Immunotherapeutics develops and researches different ways to treat cancer. It works with innovating and building cellular immunotherapies. Pluto Immunotherapeutics was founded in โฆSee details»
Q&A with Dr. Gay Crooks: โ5 Questions Withโ
Mar 29, 2022 Crooks is the co-founder of Pluto Immunotherapeutics, a startup company in the Magnify incubator at the California NanoSystems Institute that is working to build the next โฆSee details»
An exceptional partnership: How CNSIโs Magnify ... - BioscienceLA
Jul 12, 2023 Pluto Immunotherapeutics engineers and generates off-the-shelf T-cell therapies from induced-pluripotent stem cells. ... is an independent 501(c)(3) not-for-profit organization โฆSee details»
Human T Cell Generation is Restored in CD3ฮด Severe Combined ...
G.M.C. and C.S.S. are founders of Pluto Immunotherapeutics Inc and serve as consultants to this company. D.R.L. is a consultant and equity holder of Prime Medicine, Beam Therapeutics, โฆSee details»
Pluto Immunotherapeutics - Products, Competitors, Financials, โฆ
Pluto Immunotherapeutics. Frequently Asked Questions (FAQ) When was Pluto Immunotherapeutics founded? Pluto Immunotherapeutics was founded in 2020. Where is โฆSee details»
Pluto Immunotherapeutics - Crunchbase
Organization. Pluto Immunotherapeutics . Connect to CRM . Save . Summary. People. Signals & News. Similar Companies. Similar Companies. ... Pluto Immunotherapeutics and Enosi Life โฆSee details»
Pluto Immunotherapeutics - Magnify Incubator at CNSI
CNSI. 570 Westwood Plaza Building 114 | Mail Code: 722710 Los Angeles, CA 90095 Tel: (310) 267-4838 Fax: (310) 267-4918See details»
Artificial thymic organoids represent a reliable tool to study T-cell ...
Jun 17, 2020 Enzyvant has funded portions of salaries for M.L.M. and her research team. G.M.C., C.S.S., and A.M.-H. are cofounders of PLUTO Immunotherapeutics, Inc, which has โฆSee details»
Disclosures - American Society of Hematology
Nov 2, 2023 CART19/20 was developed by engineering autologous naïve/memory T (T N/MEM) cells with a bispecific anti-CD19/CD20 chimeric antigen receptor (CAR) with the goal of โฆSee details»
Strength of CAR signaling determines T cell versus ILC โฆ
A.M.-H. is a current employee of Pluto Immunotherapeutics. Supplemental information (4) PDF (5.53 MB) Document S1. Figures S1โS7. File (261.04 KB) Table S1. UMAP global markers โฆSee details»
Venetoclax and Azacitidine in the Treatment of
Jun 14, 2023 Patents, Royalties, Other Intellectual Property: Pluto Immunotherapeutics. Other Relationship: Amgen, Pluto Immunotherapeutics. No other potential conflicts of interest were โฆSee details»
An exceptional partnership: How CNSIโs Magnif | EurekAlert!
Jul 7, 2023 Pluto Immunotherapeutics engineers and generates off-the-shelf T-cell therapies from induced-pluripotent stem cells. For Amélie Montel-Hagen, Chief Scientific Officer and co โฆSee details»
Bacterial and Bacteriophage Consortia Are Associated with โฆ
Nov 2, 2023 van den Brink:Nektar Therapeutics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Pluto Immunotherapeutics: Consultancy, โฆSee details»
March 29, 2022 | Q&A with Dr. Gay Crooks: โ5 Questions Withโ
Mar 29, 2022 Dr. Crooks is the Rebecca Smith Professor in the Department of Pathology & Laboratory Medicine and Professor of Pediatrics in the David Geffen School of Medicine โฆSee details»
Strength of CAR signaling determines T cell versus ILC ...
8Present address: Pluto Immunotherapeutics, Los Angeles, CA, USA 9Present address: F. Widjaja In๏ฌammatory Bowel Disease Institute, Cedars Sinai Medical Center, 8700 Beverly โฆSee details»
Venetoclax and Azacitidine in the Treatment of NPM1-Mutated โฆ
Jun 14, 2023 Patents, Royalties, Other Intellectual Property: Pluto Immunotherapeutics. Other Relationship: Amgen, Pluto Immunotherapeutics. No other potential conflicts of interest were โฆSee details»
CCR1-Targeting CAR T Cells for Acute Myeloid Leukemia
Nov 2, 2023 James:MSKCC: Patents & Royalties: Pending patents related to leucine zipper sorting technology.van den Brink:Thymofox: Consultancy, Honoraria, Membership on an โฆSee details»
Self-regulating CAR-T cells modulate cytokine release syndrome in ...
Apr 12, 2024 Y.Y. Chen is a founder of, holds equity in, and receives consulting fees from ImmPACT Bio. Y.Y. Chen is a member of the scientific advisory board of and holds equity in โฆSee details»
Base Editing of Hematopoietic Stem Cells Rescues T-Cell โฆ
Nov 15, 2022 Methods and Results: Preliminary data in a clonal Jurkat T-cell disease model (CD3D(C202T) Jurkat T cells) revealed 93 ± 2.3% (mean ± SD) correction of CD3D c.202C>T โฆSee details»